Decapeptyl®, Neo Decapeptyl®, Trelstar®, Pamorelin®, Triptodur®
Triptorelin is a gonadotropin releasing hormone (GnRH) agonist
Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®/Triptodur®, is a GnRH agonist analogue. An agonist is a chemical that binds to a receptor of a cell and triggers a response by that cell. Triptorelin decreases the serum testosterone to castrate levels (estradiol in females).
Androgen deprivation stops the growth of the androgen dependent prostate cancer, alleviating pain and improving thus the quality of life of patients. GnRH agonist treatment achieves similar overall survival rates in advanced prostate cancer as surgical castration.The triptorelin 1-month, 3-month and 6-month sustained release formulations have provided patients with a convenient treatment modality.
In short
GnRH discovered by Professor Andrew Schally (1971 - Tulane University), who received the Nobel Prize in 1977 for his discovery. The first synthesis of GnRH agonist Triptorelin by Professor Andrew Schally was in 1973.
Triptorelin is number one product of Ipsen in 2014.
Overview of the products
Indications
- Advanced prostate cancer
- Endometriosis
- In-vitro fertilization programs
- Uterine fibroids
- Precocious puberty
Product Characteristics
3 dosages:
- 1-month (3.75 mg)
- 3-month (11.2 mg)
- 6-month (22.5 mg)
Debiopharm Value Added
- Development and registration of the triptorelin 1-, 3- and 6-month sustained release formulations in Europe, in North America and the rest of the world
- Continuous life cycle management (new formulations, route of administration, indications)
- First worldwide registered sustained release formulation of a gonadotropin releasing hormone (GnRH) agonist in 1986.
Commercial map
- Brazil
- Canada
- United States
- United States
- India
- Israel
- Taiwan
- Singapore
- Philippines
- Switzerland
Press Releases
-
October 3, 2017Read more
Arbor Pharmaceuticals, LLC and Debiopharm International SA Announce Commercial Availability of Triptodur™, Triptorelin 6-month Formulation, for Treatment of Central Precocious…
-
June 30, 2017Read more
Debiopharm International SA and Arbor Pharmaceuticals, LLC Announce U.S. FDA Approval for Triptodur™, Triptorelin 6-month Formulation, in the Treatment of…
-
January 9, 2017Read more
Debiopharm Group’s Triptorelin 6-month Formulation Receives Approval for the Treatment of Central Precocious Puberty (CPP) in Europe
Selected Publications
-
May 19, 2015Read more
Triptorelin 6-month Formulation Shows Good Efficacy and Safety in Patients with Central Precocious Puberty (CPP)
-
December 1, 2009Read more
Triptorelin 6-Month Formulation in the Management of Patients with Locally Advanced and Metastatic Prostate Cancer
-
May 18, 2004Read more
Importance of single or blended polymer types for controlled in vitro release and plasma levels of a somatostatin analogue entrapped…